Treatment of early seropositive rheumatoid arthritis: Doxycycline plus methotrexate versus methotrexate alone

Arthritis and Rheumatism

Volumn 54, Issue 2, 2006, Pages 621-627

  O'Dell, James R ^a   Elliott, Jennifer R ^b   Mallek, Jack A ^c   Mikuls, Ted R ^a   Weaver, Cynthia A ^d   Glickstein, Scott ^e   Blakely, Kent M ^f   Hausch, Raymond ^g   Leff, Rob D ^g  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c Central Plains Clinic   (United States)

^d Black Hills Neurology and Rheumatology   (United States)

^e PARK NICOLLET CLINIC   (United States)

^f Platte Valley Medical Group   (United States)

^g Duluth Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXYCYCLINE; METHOTREXATE; PLACEBO;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBACTERIAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; HEART INFARCTION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DOXYCYCLINE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HEALTH STATUS; HUMANS; MALE; METALLOPROTEASES; METHOTREXATE; MIDDLE AGED; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 32444441470     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21620     Document Type: Article

References (29)

1. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomized comparison of combination step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
2. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al, and the FIN-RACo trial group. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomized trial. Lancet 1999;353:1568-73.
3. Calguneri M, Pay S, Caliskaner Z, Apras S, Kiraz S, Ertenli I, et al. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin Exp Rheumatol 1999;17:699-704.
4. Mikuls TR, O'Dell J. The changing face of rheumatoid arthritis therapy: results of serial surveys [concise communication]. Arthritis Rheum 2000;43:464-5.
5. O'Dell JR, Haire CE, Palmer W, Drymalski W, Wees S, Blakely K, et al. Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1997;40:842-8.
6. O'Dell JR, Blakely KW, Mallek JA, Eckhoff PJ, Left RD, Wees SJ, et al. Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 2001;44:2235-41.
7. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
8. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
9. Egger MJ, Huth DA, Ward JR, Reading JC, Williams HJ. Reduced joint count indices in the evaluation of rheumatoid arthritis. Arthritis Rheum 1985;28:613-9.
10. Kloppenburg M, Breedveld FC, Terwiel JP, Mallee C, Dijkmans BA. Minocycline in active rheumatoid arthritis: a double-blind, placebo-controlled trial. Arthritis Rheum 1994;37:629-36.
11. Tilley BC, Alarcon GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, et al, and the MIRA Trial Group. Minocycline in rheumatoid arthritis: a 48-week, double-blind, placebo-controlled trial. Ann Intern Med 1995;122:81-9.
12. O'Dell JR, Paulsen G, Haire CE, Blakely K, Palmer W, Wees SJ, et al. Treatment of early seropositive rheumatoid arthritis with minocycline: four-year followup of a double-blind, placebo-controlled trial. Arthritis Rheum 1999;42:1691-5.
13. Van der Laan W, Molenaar E, Ronday K, Verheijen J, Breedveld F, Greenwald R, et al. Lack of effect of doxycycline on disease activity and joint damage in patients with rheumatoid arthritis: a double-blind, placebo controlled trial. J Rheumatol 2001;28:1967-74.
14. St.Clair EW, Wilkinson WE, Pisetsky DS, Sexton DJ, Drew R, Krause VB, et al. The effects of intravenous doxycycline therapy for rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2001;44:1043-7.
15. Pillemer S, Gulko P, Ligier S, Yarboro C, Gourley M, Goldbach-Mansky R, et al. Pilot clinical trial of intravenous doxycycline versus placebo for rheumatoid arthritis. J Rheumatol 2003;30:41-3.
16. Sreekanth VR, Handa R, Wali JP, Aggarwal P, Dwivedi SN. Doxycycline in the treatment of rheumatoid arthritis: a pilot study. J Assoc Physicians India 2000;48:804-7.
17. Stone M, Fortin PR, Pacheco-Tena C, Inman RD. Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity. J Rheumatol 2003;30:2112-22.
18. Golub LM, Lee HM, Lehrer G, Nemiroff A, McNamara TF, Kaplan R, et al. Minocycline reduces gingival collagenolytic activity with diabetes: preliminary observations and a proposed new mechanism of action. J Periodontal Res 1983;18:516-26.
19. Golub LM, Ramamurthy NS, McNamara TF, Gomes B, Wolff M, Casino A. Tetracyclines inhibit tissue collagenase activity: a new mechanism in the treatment of periodontal disease. J Periodontal Res 1984;19:651-5.
20. Ritchlin CT, Haas-Smith SA, Schwarz EM, Greenwald RA. Minocycline but not doxycycline upregulates IL-10 production in human synoviocytes, mononuclear cells and synovial explants [abstract]. Arthritis Rheum 2000;43 Suppl 9:S345.
21. Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 1991;2:297-321.
22. Vernillo AT, Ramamurthy NS, Golub LM, Rifkin BR. The nonantimicrobial properties of tetracycline for the treatment of periodontal diseases. Curr Opin Periodontol 1994;2:111-8.
23. Greenwald RA. Tetracyclines may be therapeutically beneficial in rheumatoid arthritis, but not for the reasons that you might think. J Clin Rheumatol 1995;1:185-9.
24. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, et al. A novel mechanism of action of tetracyclines: effects on nitric oxide syntheses. Proc Natl Acad Sci U S A 1996;93:14014-9.
25. Martin RR, Warr GA, Couch RB, Yeager H, Knight V. Effects of tetracycline on leukotaxis. J Infect Dis 1974;129:110-6.
26. Forsgen A, Schmeling D, Quie PG. Effect of tetracycline on the phagocytic function of human leukocytes. J Infect Dis 1974;130:412-5.
27. Yu LP Jr, Smith GN Jr, Brandt KD, Capello WN. Preoperative oral administration of doxycycline reduces collagenase activity in extracts of human osteoarthritis cartilage [abstract]. Arthritis Rheum 1994;37 Suppl 9:S362.
28. Schlienger RG, Bircher AJ, Meier CR. Minocycline-induced lupus: a systematic review. Dermatology 2000;200:223-31.
29. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.